While the latest trial didn't yield the hoped-for results in myelodysplastic syndrome, the potential for sickle cell anemia remains. Could this drug be the key to transforming treatment options for another chronic condition? 🌟
Agios' PK activator fails in myelodysplastic syndrome but keeps hope for sickle cell anemia - Sinaptica
What happened?
Agios Pharmaceuticals announced on May 29, 2026, that its experimental drug tebapivat, a next-generation oral pyruvate kinase (PK) activator, did
sinapti.ca
May 29, 2026 at 8:11 PM
While the latest trial didn't yield the hoped-for results in myelodysplastic syndrome, the potential for sickle cell anemia remains. Could this drug be the key to transforming treatment options for another chronic condition? 🌟
Un ensayo con 65 pacientes no logró demostrar el beneficio esperado en el tratamiento de síndromes mielodisplásicos. ¿Qué significa esto para el futuro de los activadores de piruvato kinasa en otras condiciones como la anemia falciforme? 🩸
El activador PK de Agios fracasa en síndrome mielodisplásico pero mantiene la esperanza para la anemia falciforme - Sinaptica
¿Qué pasó?
Agios Pharmaceuticals anunció el 29 de mayo de 2026 que su fármaco experimental tebapivat, un activador oral de piruvato kinasa (PK) de nueva generac
sinapti.ca
May 29, 2026 at 8:11 PM
Un ensayo con 65 pacientes no logró demostrar el beneficio esperado en el tratamiento de síndromes mielodisplásicos. ¿Qué significa esto para el futuro de los activadores de piruvato kinasa en otras condiciones como la anemia falciforme? 🩸
Pomerantz Law Firm Investigates Agios Pharmaceuticals for Potential Investor Fraud#USA#New_York#Pomerantz_LLP#Agios_Pharmaceuticals#tebapivat
Pomerantz Law Firm Investigates Agios Pharmaceuticals for Potential Investor Fraud
The Pomerantz Law Firm is looking into claims from investors regarding potential securities fraud at Agios Pharmaceuticals, prompting inquiries into recent business practices.
third-news.com
August 7, 2026 at 3:26 AM
Pomerantz Law Firm Investigates Agios Pharmaceuticals for Potential Investor Fraud#USA#New_York#Pomerantz_LLP#Agios_Pharmaceuticals#tebapivat
Agios scraps sickle cell drug programme on underwhelming Phase II data
This SCD termination deals another blow to Agios' tebapivat prospects following its May 2026 termination in MDS due to efficacy concerns. The post Agios scraps sickle cell drug programme on underwhelming Phase II data appeared…
This SCD termination deals another blow to Agios' tebapivat prospects following its May 2026 termination in MDS due to efficacy concerns. The post Agios scraps sickle cell drug programme on underwhelming Phase II data appeared…
Agios scraps sickle cell drug programme on underwhelming Phase II data
This SCD termination deals another blow to Agios' tebapivat prospects following its May 2026 termination in MDS due to efficacy concerns. The post Agios scraps sickle cell drug programme on underwhelming Phase II data appeared first on Clinical Trials Arena .
news-area.com
July 22, 2026 at 1:57 AM
Agios scraps sickle cell drug programme on underwhelming Phase II data
This SCD termination deals another blow to Agios' tebapivat prospects following its May 2026 termination in MDS due to efficacy concerns. The post Agios scraps sickle cell drug programme on underwhelming Phase II data appeared…
This SCD termination deals another blow to Agios' tebapivat prospects following its May 2026 termination in MDS due to efficacy concerns. The post Agios scraps sickle cell drug programme on underwhelming Phase II data appeared…
Feed: "MedCity News"
By: Frank Vinluan on Tuesday, July 21, 2026
By: Frank Vinluan on Tuesday, July 21, 2026
Agios Pharma Drops Sickle Cell Disease Drug After Phase 2 Data Disappoint
Agios Pharmaceuticals said tebapivat fell short of expectations in a Phase 2 test in sickle cell disease. It’s the latest in a series of disappointing industry developments in sickle cell disease.
medcitynews.com
July 22, 2026 at 1:33 AM
Feed: "MedCity News"
By: Frank Vinluan on Tuesday, July 21, 2026
By: Frank Vinluan on Tuesday, July 21, 2026
📰 #Finance
Agios pares loss after abandoning sickle cell asset tebapivat
seekingalpha.com
July 21, 2026 at 6:26 PM
📰 #Finance
#$AGIO announced it will not advance tebapivat in sickle cell disease after Phase 2 results failed to show a differentiated profile. notreload.xyz/xy/agios-dis...
Agios Discontinues Tebapivat in Sickle Cell Disease
Agios Pharmaceuticals announced it will not advance tebapivat in sickle cell disease after Phase 2 results failed to show a differentiated profile.
notreload.xyz
July 21, 2026 at 12:26 PM
#$AGIO announced it will not advance tebapivat in sickle cell disease after Phase 2 results failed to show a differentiated profile. notreload.xyz/xy/agios-dis...
#AGIO Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
https://www.stocktitan.net/news/AGIO/agios-provides-update-on-phase-2-trial-of-tebapivat-in-sickle-cell-tjrs8p5oibz3.html
https://www.stocktitan.net/news/AGIO/agios-provides-update-on-phase-2-trial-of-tebapivat-in-sickle-cell-tjrs8p5oibz3.html
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a differentiated profile to support continued development in sickle cell disease Safety and tolerability of tebapivat were consistent with prior sickle cell
www.stocktitan.net
July 21, 2026 at 11:00 AM
#AGIO Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
https://www.stocktitan.net/news/AGIO/agios-provides-update-on-phase-2-trial-of-tebapivat-in-sickle-cell-tjrs8p5oibz3.html
https://www.stocktitan.net/news/AGIO/agios-provides-update-on-phase-2-trial-of-tebapivat-in-sickle-cell-tjrs8p5oibz3.html
#AgiosPharma has said it will halt clinical development of tebapivat, a PK activator that had reached phase 2 testing in #sicklecell disease, causing a slump in its share price.
Agios shares slide as it abandons sickle cell candidate
Agios Pharma has said it will halt clinical development of tebapivat, a PK activator that had reached phase 2 testing in sickle cell disease.
buff.ly
July 21, 2026 at 1:30 PM
#AgiosPharma has said it will halt clinical development of tebapivat, a PK activator that had reached phase 2 testing in #sicklecell disease, causing a slump in its share price.
A new global clinical trial led by Scarborough Health Network is advancing groundbreaking sickle cell research. As the first hospital in Ontario to offer the tebapivat trial, SHN is helping expand access to innovative treatments for people living with SCD: www.oha.com/news/new...
February 23, 2026 at 6:00 PM
A new global clinical trial led by Scarborough Health Network is advancing groundbreaking sickle cell research. As the first hospital in Ontario to offer the tebapivat trial, SHN is helping expand access to innovative treatments for people living with SCD: www.oha.com/news/new...
#$AGIO scraps LR-MDS drug tebapivat after weak results but continues sickle cell trials; safety was good. notreload.xyz/xy/agios-sto...
Agios Stops Tebapivat in LR-MDS
Agios scraps LR-MDS drug tebapivat after weak results but continues sickle cell trials; safety was good.
notreload.xyz
May 29, 2026 at 11:23 AM
#$AGIO scraps LR-MDS drug tebapivat after weak results but continues sickle cell trials; safety was good. notreload.xyz/xy/agios-sto...
#AGIO Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
https://www.stocktitan.net/news/AGIO/agios-provides-update-on-phase-2b-trial-of-tebapivat-in-lower-risk-5ifvjdljpqsm.html
https://www.stocktitan.net/news/AGIO/agios-provides-update-on-phase-2b-trial-of-tebapivat-in-lower-risk-5ifvjdljpqsm.html
Agios to stop tebapivat in LR-MDS, plans sickle cell data in 2H 2026
Phase 2b LR-MDS trial failed to meet Agios’ predefined threshold, so it will not advance tebapivat in this use; topline sickle cell data are planned for 2H 2026.
www.stocktitan.net
May 29, 2026 at 11:00 AM
#AGIO Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
https://www.stocktitan.net/news/AGIO/agios-provides-update-on-phase-2b-trial-of-tebapivat-in-lower-risk-5ifvjdljpqsm.html
https://www.stocktitan.net/news/AGIO/agios-provides-update-on-phase-2b-trial-of-tebapivat-in-lower-risk-5ifvjdljpqsm.html
Agios narrows ambitions for tebapivat after study miss in lower-risk MDS #$AGIO firstwordpharma.com/story/7487784
May 29, 2026 at 2:56 PM
Agios narrows ambitions for tebapivat after study miss in lower-risk MDS #$AGIO firstwordpharma.com/story/7487784